Search filters
Filters
Clear All

Phase

  • 54
  • 61
  • 2
  • 53
  • 1
  • 51
  • 11
  • 670
  • 926
  • 606
  • 5
  • 39
  • 886

Found 930 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 16323: Neoadjuvant/Phase 1 Study of CD40 Agonist (LVGN7409) and PD-1 Inhibitor (LVGN3616) in Patients with Resectable HPV-Negative Mucosal Head/Neck Squamous Cell Carcinoma (HNSCC)

99 years and younger
All genders
Please refer to Protocol Section 3 (Study Objectives and Endpoints). Please refer to Protocol Section 3 (Study Objectives and Endpoints). Please refer to Protocol Section 3 (Study Objectives and Endpoints).
Learn More

EA2185

99 years and younger
All genders
The purpose of this study is to compare the two approaches for monitoring pancreatic cysts. The doctors want to see if less frequent monitoring is better or worse than more frequent monitoring for patients with pancreatic cysts. Depending on the Group you are assign to you receive a CT or …
Learn More

S2107 Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer

99 years and younger
All genders
This phase II trial tests whether adding nivolumab to the usual treatment (encorafenib and cetuximab) works better than the usual treatment alone to shrink tumors in patients with colorectal cancer that has spread to other places in the body (metastatic) or that cannot be removed by surgery (unresectable) and whose …
Learn More

EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

99 years and younger
All genders
To examine whether the addition of nivolumab, a monoclonal antibody specific for human programmed death-1 (PD-1) receptor expressed on T cells, after chemoradiation can provide a survival benefit in patients with locally advanced high-risk anal cancer
Learn More

UPCC 29123: CAMBRIA-1: A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy

99 years and younger
All genders
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy for at …
Learn More

Cannabis use and outcomes for cancer

99 years and younger
All genders
Assess if cannabis use over time is associated with changes in key Patient Reported Outcomes (PRO) and opioid use over time. We will enroll 600 participants, each site will include 100 cannabis users 100 cannabis non-users diagnosed with cancer in the last 3 years and prescribed opioids. We will collect …
Learn More

UPCC 21123 A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were Previously Treated with T-DXd

99 years and younger
All genders
A Global, Single Arm, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd. The ARX788 will be administered every 3 weeks (Q3W) intravenous (IV) infusion. We would like to rely on WCG IRB as the IRB of record for this study.
Learn More

A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to eltrombopag in primary immune thrombocytopenia (ITP) patients who failed steroids

99 years and younger
All genders
PURPOSE The overall objective is to demonstrate that the addition of ianalumab (either 3mg/kg or 9mg/kg dosage) to standard care (eltrombopag) is more effective and safer compared to the standard of care (eltrombopag) alone. Primary outcome variable is determined by the time to treatment failure which is in turn determined …
Learn More

A phase 2 study of ianalumab (VAY736) in patients with primary immune thrombocytopenia (ITP) previously treated with at least two lines of therapies

99 years and younger
All genders
PURPOSE To evaluate the efficacy of ianalumab (i.e., platelet response 50 G/L) in participants with primary ITP previously treated with at least a corticosteroid and a TPO-RA. A platelet count of 50 G/L at two (or more) consecutive assessments at least 7 days apart between Week 1 Day 1 and …
Learn More

BACKBEAT Trial)

99 years and younger
All genders
Investigational Atrioventricular Interval Modulation (AVIM) software will be loaded onto commercially available Pacemakers (PPM), such as the Medtronic Azure/Astra devices. Therefore, the Azure/Astra devices will be considered investigational while the AVIM is present. AVIM therapy is indicated for the reduction of blood pressure in patients with dual PPM and uncontrolled …
Learn More
671 - 680 of 930